The FDA extended Exelixis’ review of zanzalintinib with atezolizumab for metastatic colorectal cancer by three months. The updated March 3, 2027 action date gives investors the next stated regulatory milestone after Exelixis submitted safety and efficacy data that the agency classified as a major amendment.

Key Highlights

  • The agency classified Exelixis’ updated safety and efficacy data as a major amendment.
  • The updated PDUFA action date is March 3, 2027, for zanzalintinib with atezolizumab in metastatic colorectal cancer.
  • The FDA requested information, and Exelixis submitted updated safety and efficacy data.

EXELIXIS, INC. (NASDAQ: EXEL) said the FDA extended its review of zanzalintinib with atezolizumab for metastatic colorectal cancer by three months.

Updated Safety And Efficacy Data

The application covers zanzalintinib in combination with atezolizumab for patients with metastatic colorectal cancer. Exelixis submitted updated safety and efficacy information after an FDA information request. The agency designated that updated submission a major amendment. The FDA’s notification on September 10, 2026 concerned the new drug application and the review period attached to that application. Brenda J. Hefti signed the update on September 11, 2026 as senior vice president and general counsel.

March 3, 2027 FDA Milestone

The filing identifies the updated PDUFA action date as March 3, 2027. The FDA extended the review period by three months. The FDA deemed the updated safety and efficacy data a major amendment. The FDA review concerns the zanzalintinib and atezolizumab combination for metastatic colorectal cancer.